Related Experiment Video
Updated: Aug 11, 2026
Robotic Duodenum-preserving Total Pancreatic Head Resection for Intraductal Papillary Mucinous Neoplasms
Published on: April 17, 2026
[Recent advances in digestive oncology (pancreas excluded)]
1Département de chirurgie digestive carcinologique, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif Cedex. elias@igr.fr
Abstract:
The present manuscript focus on new data regarding gastro-intestinal (GI) tumors (pancreas excluded). Two mains issues are discussed: advances in terms of the molecular basis of GI oncogenesis, and the data on molecular targeted agents for which the cost/efficacity balance needs to be addressed.
Insights
This study reviews recent advances in gastro-intestinal (GI) tumor molecularS and targeted therapies. It examines the molecular underpinnings of GI cancer development and the cost-effectiveness of novel treatments.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Context:
- Gastro-intestinal (GI) tumors, excluding pancreatic cancer, represent a significant area of oncological research.
- Understanding the molecular basis of GI oncogenesis is crucial for developing effective treatments.
Purpose:
- To present new data on the molecular basis of GI tumor development.
- To discuss molecular targeted agents for GI cancers, focusing on their cost-effectiveness.
Summary:
- The manuscript explores recent findings in the molecular mechanisms driving gastro-intestinal cancer.
- It reviews molecular targeted therapies, emphasizing the need to evaluate their cost-benefit ratio for clinical application.
Impact:
- Provides insights into the molecular landscape of GI cancers.
- Informs clinical decision-making regarding the adoption of targeted therapies based on efficacy and economic factors.
